Clinical Trials Directory

Trials / Unknown

UnknownNCT03982290

Psychophysiological Effects of Lactobacillus Plantarum PS128 in Preschool Children With Autism Spectrum Disorder

Psychophysiological Effects of Lactobacillus Plantarum PS128 in Preschool Children With Autism Spectrum Disorder: a Randomized, Placebo-controlled Trial

Status
Unknown
Phase
N/A
Study type
Interventional
Enrollment
250 (estimated)
Sponsor
Mackay Memorial Hospital · Academic / Other
Sex
All
Age
30 Months – 7 Years
Healthy volunteers
Accepted

Summary

Autism Spectrum Disorders (ASD) comprises a complex group of disorders of neuronal development characterized by social and communication impairment along with presence of repetitive and restrictive behaviors. Emerging evidences support the gut-brain axis and further microbiota-gut-brain axis. Elevated prevalence of gastrointestinal (GI) dysfunction in individuals with ASD suggested that targeting gut may benefit patients with ASD. Lactobacillus plantarum PS128 (PS128) was reported to be a psychobiotic in several animal studies which modulated the levels of neurotransmitters in different brain areas. The current randomized, placebo-controlled trial was conducted to investigate the psychophysiological effects of PS128 in preschool children with ASD.

Detailed description

Emerging evidences support the gut-brain axis and further microbiota-gut-brain axis. Elevated prevalence of gastrointestinal (GI) dysfunction in individuals with ASD suggested that targeting gut may benefit patients with ASD. Lactobacillus plantarum PS128 (PS128) was reported to be a psychobiotic in several animal studies which modulated the levels of neurotransmitters in different brain areas. The current randomized, placebo-controlled trial was conducted to investigate the psychophysiological effects of PS128 in preschool children with ASD.

Conditions

Interventions

TypeNameDescription
OTHERProbiotic, Lactobacillus plantarum PS128PS128 capsules, 2 capsules per day
OTHERPlacebo, microcrystalline cellulosePlacebo capsules, 2 capsules per day

Timeline

Start date
2018-10-01
Primary completion
2019-12-01
Completion
2020-12-01
First posted
2019-06-11
Last updated
2019-06-11

Locations

1 site across 1 country: Taiwan

Source: ClinicalTrials.gov record NCT03982290. Inclusion in this directory is not an endorsement.